This follows post #2 rather than contradicting it.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
post #13 is right about the mechanism and I think understates the practical bit.
Hepatic steatosis and MASH: a phase 2 trial in semaglutide for steatohepatitis showed resolution was more frequent on treatment. Histological resolution is a surrogate for long-term clinical outcomes like cirrhosis.
Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific medications and doses with a clinician familiar with bariatric surgery is prudent.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
Read the full topic (39 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Hepatic steatosis: what the MASH trial evidence supports — one year on
On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
2 | 4.1k | 6mo | |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published…
|
+19 | 23 | 311 | 12d |
|
Hepatic steatosis: what the MASH trial evidence supports
Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Asking about a population rather than about a person. The published trials in…
|
+77 | 83 | 950 | 13mo |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
|
+17 | 22 | 4.5k | 1d |
|
Hypertension improvement and when medication needs revisiting — a second dataset
Posting this under the heading it deserves: Hypertension improvement and when medication needs revisiting — a second dataset Everything below is what sits behind that. General question, not a request for…
|
+126 | 133 | 22k | 21mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Cardiovascular risk: reading the outcome trials as a set
Cardiovascular risk: reading the outcome trials as a set Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
4 | 12k | 5mo | |
|
People with a low starting BMI: where the evidence stops
Posting this under the heading it deserves: People with a low starting BMI: where the evidence stops Everything below is what sits behind that. Asking about a population rather than about a person. The…
|
+23 | 27 | 5.8k | 19mo |
|
Type 2 diabetes and the largest part of the evidence base — does this still hold?
Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…
|
+18 | 25 | 1.7k | 22mo |
|
Renal impairment: what the labelling says about dose
On the subject in the title: Renal impairment: what the labelling says about dose Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
|
4 | 8.9k | 19mo | |
|
Hepatic steatosis: what the MASH trial evidence supports — one year on
On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
2 | 4.1k | 6mo |